Potential of <em>DEK</em> proto‑oncogene as a prognostic biomarker for colorectal cancer: An evidence‑based review

Habiburrahman,Muhammad; Wardoyo,Muhammad Prasetio; Sutopo,Stefanus; Rahadiani,Nur

doi:10.3892/mco.2022.2550

Potential of DEK proto‑oncogene as a prognostic biomarker for colorectal cancer: An evidence‑based review

Authors:
- Muhammad Habiburrahman
- Muhammad Prasetio Wardoyo
- Stefanus Sutopo
- Nur Rahadiani
View Affiliations

Affiliations: Faculty of Medicine, Universitas Indonesia/Dr Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia, Department of Anatomical Pathology, Faculty of Medicine Universitas Indonesia/Dr Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia
Published online on: May 26, 2022 https://doi.org/10.3892/mco.2022.2550
Article Number: 117
Copyright: © Habiburrahman et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Given its role in tumorigenesis and its correlation with various pathologic features of colorectal cancer (CRC), DEK is considered to have the potential to predict CRC prognosis. This review attempts to summarize current knowledge and evidence supporting the potential of DEK as a prognostic biomarker of CRC. We searched meta‑analyses, systematic reviews, cohort studies, and cell line studies published in the last 10 years. A literature search was conducted in PubMed, Pubmed Central (PMC), Proquest, EBSCOHost, Scopus, and Cochrane Library using the keywords ‘colorectal/colon/rectal cancer’, ‘DEK’, ‘biomarker’, and ‘prognosis’. Studies that were not published in English, without accessible full text, unrelated to clinical questions, or conducted with a design unsuitable for the eligibility criteria were excluded. Seven included studies reported the potential of DEK as a prognostic biomarker of CRC and its role in cancer cell proliferation, invasion, and metastasis. This role is achieved through the Wnt/β‑catenin pathway, prevention of apoptosis through destabilization of p53, and bridging inflammation and tumorigenesis through the nuclear factor (NF)‑κβ pathway, causing chronic inflammation and activation of tumorigenic genes. DEK overexpression is also associated with CRC clinical and pathological features, such as tumor size, lymph node metastasis, serosal invasion, differentiation, tumor staging, and epithelial‑mesenchymal transition. DEK overexpression was found to be associated with lower survival and recovery rates. Its prognostic value was comparable with other prognostic biomarkers of CRC, such as BRAF, topoisomerase‑1, and CEA. A cohort study reported that DEK overexpression was associated with a better response to fluoropyrimidine‑based chemotherapy, while a cell‑line study indicated a correlation between DEK overexpression with a worse response to irinotecan‑based chemotherapy. In conclusion, considering its correlation with CRC pathology, its association with worse CRC patient survival, and its possibility to forecast the therapeutic response of various chemotherapeutic regimens, DEK has the potential to be used as a CRC prognostic biomarker.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
2	Surveillance Epidemiology, End Results (SEER) Program: SEER*Stat Database: Incidence - SEER 18 Regs Research Data.Nov 2015 Sub (1973-2013) - Linked To County Attributes - Total U.S., 1969-2014 Counties. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April. 2016, based on the November 2015 submission. National Cancer Institute, Maryland, 2016.
3	Barnett A, Cedar A, Siddiqui F, Herzig D, Fowlkes E and Thomas CR Jr: Colorectal cancer emergencies. J Gastrointest Cancer. 44:132–142. 2013.PubMed/NCBI View Article : Google Scholar
4	Glynne-Jones R, Brown G, Chau I and Moran BJ: Colon and rectum. In: UICC Manual of Clinical Oncology. 9th edition. O'Sullivan B, Brierley J, D'Cruz AK, Fey MF, Pollock R, Vermorken JB and Huang SH (eds.) John Wiley and Sons, Ltd., Chichester West Sussex, UK Hoboken, NJ, pp308-326, 2015.
5	Jessup JM, Goldberg RM, Asare EA, Benson AB, Brierley JD, Chang GJ, Chen V, Compton CC, De Nardi P, Goodman KA, et al: Colon and Rectum. In: AJCC Cancer Staging Manual 8th Edition. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al (eds.) Springer International Publishing, 251-274, 2017.
6	Loughrey MB, Webster F, Arends MJ, Brown I, Burgart LJ, Cunningham C, Flejou JF, Kakar S, Kirsch R, Kojima M, et al: Dataset for Pathology Reporting of Colorectal Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Ann Surg. 275:e549–e561. 2022.PubMed/NCBI View Article : Google Scholar
7	Kim BH, Kim JM, Kang GH, Chang HJ, Kang DW, Kim JH, Bae JM, Seo AN, Park HS, Kang YK, et al: Standardized pathology report for colorectal cancer, 2nd edition. J Pathol Transl Med. 54:1–19. 2020.PubMed/NCBI View Article : Google Scholar
8	Maguire A and Sheahan K: Controversies in the pathological assessment of colorectal cancer. World J Gastroenterol. 20:9850–9861. 2014.PubMed/NCBI View Article : Google Scholar
9	Diamandis EP: Cancer biomarkers: Can we turn recent failures into success? J Natl Cancer Inst. 102:1462–1467. 2010.PubMed/NCBI View Article : Google Scholar
10	Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C and Topolcan O: Tumour markers in colorectal cancer: European Group on tumour markers (EGTM) guidelines for clinical use. Eur J Cancer. 43:1348–1360. 2007.PubMed/NCBI View Article : Google Scholar
11	Pease NA, Wise-Draper T and Privette Vinnedge L: Dissecting the potential interplay of DEK functions in inflammation and cancer. J Oncol. 2015(106517)2015.PubMed/NCBI View Article : Google Scholar
12	Holloway S and Peart J: Evidence-based reviews: Principles and methodological considerations. Wounds UK. 14:26–32. 2018.
13	Siwek J, Gourlay ML, Slawson DC and Shaughnessy AF: How to write an evidence-based clinical review article. Am Fam Physician. 65:251–258. 2002.PubMed/NCBI
14	Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, Moschetti I, Phillips B, Thornton H, Goddard O, et al: The Oxford 2011levels of evidence. 2011. https://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf.
15	Liu G, Xiong D, Zeng J, Xu G, Xiao R, Chen B and Huang Z: Prognostic role of DEK in human solid tumors: A meta-analysis. Oncotarget. 8:98985–98992. 2017.PubMed/NCBI View Article : Google Scholar
16	Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J and Lin Z: DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer. 13(366)2013.PubMed/NCBI View Article : Google Scholar
17	Martinez-Useros J, Moreno I, Fernandez-Aceñero MJ, Rodriguez-Remirez M, Borrero-Palacios A, Cebrian A, Gomez Del Pulgar T, Del Puerto-Nevado L, Li W, Puime-Otin A, et al: The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer. BMC Cancer. 18(144)2018.PubMed/NCBI View Article : Google Scholar
18	Martinez-Useros J, Rodriguez-Remirez M, Borrero-Palacios A, Moreno I, Cebrian A, Gomez del Pulgar T, del Puerto-Nevado L, Vega-Bravo R, Puime-Otin A, Perez N, et al: DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. BMC Cancer. 14(965)2014.PubMed/NCBI View Article : Google Scholar
19	You S, Guan Y and Li W: Epithelial-mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3. Mol Med Rep. 17:1065–1070. 2018.PubMed/NCBI View Article : Google Scholar
20	Babaei-Jadidi R, Li N, Saadeddin A, Spencer-Dene B, Jandke A, Muhammad B, Ibrahim EE, Muraleedharan R, Abuzinadah M, Davis H, et al: FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J Exp Med. 208:295–312. 2011.PubMed/NCBI View Article : Google Scholar
21	Lin L, Piao J, Ma Y, Jin T, Quan C, Kong J, Li Y and Lin Z: Mechanisms underlying cancer growth and apoptosis by DEK overexpression in colorectal cancer. PLoS One. 9(e111260)2014.PubMed/NCBI View Article : Google Scholar
22	Witkiewicz AK, Balaji U and Knudsen ES: Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers. Clin Cancer Res. 20:4837–4848. 2014.PubMed/NCBI View Article : Google Scholar
23	Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, Asamura H, Matsuno Y, Kondo T, Imoto I, et al: DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene. 29:4671–4681. 2010.PubMed/NCBI View Article : Google Scholar
24	Hu H, Scholten I, Gruss C and Knippers R: The distribution of the DEK protein in mammalian chromatin. Biochem Biophys Res Commun. 358:1008–1014. 2007.PubMed/NCBI View Article : Google Scholar
25	Kappes F, Scholten I, Richter N, Gruss C and Waldmann T: Functional domains of the ubiquitous chromatin protein DEK. Mol Cell Biol. 24:6000–6010. 2004.PubMed/NCBI View Article : Google Scholar
26	Sandén C and Gullberg U: The DEK oncoprotein and its emerging roles in gene regulation. Leukemia. 29:1632–1636. 2015.PubMed/NCBI View Article : Google Scholar
27	Waldmann T, Eckerich C, Baack M and Gruss C: The ubiquitous chromatin protein DEK alters the structure of DNA by introducing positive supercoils. J Biol Chem. 277:24988–24994. 2002.PubMed/NCBI View Article : Google Scholar
28	von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A and Grosveld G: The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol. 12:1687–1697. 1992.PubMed/NCBI View Article : Google Scholar
29	Sitwala KV, Adams K and Markovitz DM: YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter. Oncogene. 21:8862–8870. 2002.PubMed/NCBI View Article : Google Scholar
30	Lamond AI and Spector DL: Nuclear speckles: A model for nuclear organelles. Nat Rev Mol Cell Biol. 4:605–612. 2003.PubMed/NCBI View Article : Google Scholar
31	Kappes F, Khodadoust MS, Yu L, Kim DS, Fullen DR, Markovitz DM and Ma L: DEK expression in melanocytic lesions. Hum Pathol. 42:932–938. 2011.PubMed/NCBI View Article : Google Scholar
32	Carro MS, Spiga FM, Quarto M, Ninni VD, Volorio S, Alcalay M and Müller H: DEK expression is controlled by E2F and deregulated in diverse tumor type. Cell Cycle. 5:1202–1207. 2006.PubMed/NCBI View Article : Google Scholar
33	Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S, Goseki N, Matsubara O and Takenaka K: Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 59:4990–4996. 1999.PubMed/NCBI
34	Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS, Yong VW, Mkrdichian E, Cerullo L, Leestma J and Moskal JR: The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett. 156:191–198. 2000.PubMed/NCBI View Article : Google Scholar
35	Casas S, Nagy B, Elonen E, Aventín A, Larramendy ML, Sierra J, Ruutu T and Knuutila S: Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leuk Lymphoma. 44:1935–1941. 2003.PubMed/NCBI View Article : Google Scholar
36	Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin R and Lin Z: Clinicopathological significance of DEK overexpression in serous ovarian tumors. Pathol Int. 59:443–447. 2009.PubMed/NCBI View Article : Google Scholar
37	Privette Vinnedge LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE and Wells SI: The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene. 30:2741–2752. 2011.PubMed/NCBI View Article : Google Scholar
38	Privette Vinnedge LM, Benight NM, Wagh PK, Pease NA, Nashu MA, Serrano-Lopez J, Adams AK, Cancelas JA, Waltz SE and Wells SI: The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers. Oncogene. 34:2325–2336. 2015.PubMed/NCBI View Article : Google Scholar
39	Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz DM and Soengas MS: Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res. 69:6405–6413. 2009.PubMed/NCBI View Article : Google Scholar
40	Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet. 357:539–545. 2001.PubMed/NCBI View Article : Google Scholar
41	Karin M and Greten FR: NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 5:749–759. 2005.PubMed/NCBI View Article : Google Scholar
42	Dong X, Wang J, Kabir FN, Shaw M, Reed AM, Stein L, Andrade LE, Trevisani VF, Miller ML, Fujii T, et al: Autoantibodies to DEK oncoprotein in human inflammatory disease. Arthritis Rheum. 43:85–93. 2000.PubMed/NCBI View Article : Google Scholar
43	Saha AK, Kappes F, Mundade A, Deutzmann A, Rosmarin DM, Legendre M, Chatain N, Al-Obaidi Z, Adams BS, Ploegh HL, et al: Intercellular trafficking of the nuclear oncoprotein DEK. Proc Natl Acad Sci USA. 110:6847–6852. 2013.PubMed/NCBI View Article : Google Scholar
44	Koncina E, Haan S, Rauh S and Letellier E: Prognostic and predictive molecular biomarkers for colorectal cancer: Updates and challenges. Cancers (Basel). 12(319)2020.PubMed/NCBI View Article : Google Scholar
45	Jawad N, Direkze N and Leedham SJ: Inflammatory Bowel disease and colon cancer. In: Inflammation and Gastrointestinal Cancers. Jankowski JAZ (ed.) Springer, Berlin, Heidelberg, pp99-115, 2011.